EP1274693A1 - Method for producing 2,5-diketopiperazines, 2,5-diketopiperazines, dipeptides and the use thereof - Google Patents

Method for producing 2,5-diketopiperazines, 2,5-diketopiperazines, dipeptides and the use thereof

Info

Publication number
EP1274693A1
EP1274693A1 EP01927786A EP01927786A EP1274693A1 EP 1274693 A1 EP1274693 A1 EP 1274693A1 EP 01927786 A EP01927786 A EP 01927786A EP 01927786 A EP01927786 A EP 01927786A EP 1274693 A1 EP1274693 A1 EP 1274693A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
diketopiperazines
dipeptides
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01927786A
Other languages
German (de)
French (fr)
Inventor
Karlheinz Drauz
Günter Knaup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Operations GmbH
Original Assignee
Degussa GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Degussa GmbH filed Critical Degussa GmbH
Publication of EP1274693A1 publication Critical patent/EP1274693A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring

Definitions

  • the present invention relates to a process for the preparation of 2, 5-diketopiperazines of the general 5 formula I,
  • alkyl (C 2 -C 8) alkenyl, (C 2 -C 8) -alkynyl, (C ⁇ -C8) alkoxy, - independently in which R 1, R 2 from each other, (C ⁇ -C 8) are H, , (C 3 - C 8 ) cycloalkyl, (C 6 -C 8 ) aryl,, (C 7 -C 9 ) aralkyl, (C 3 -C 8 ) heteroaryl, (CC 19 ) heteroaralkyl, ((-C-C 8 ) alkyl) ⁇ _ 3 - (C 3 - C 8 ) cycloalkyl, ((dC 8 ) alkyl) ⁇ _ 3 - (C 6 -C 18 ) aryl, ((C ⁇ -C 8 ) - Alkyl)!
  • R 3 , R 4 independently of one another represent H, (-C-C 8 ) -alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (-C-C 8 ) acyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 18 ) aryl, (C 7 - C 19 ) aralkyl, (C 3 -C 18 ) heteroaryl, (C 4 -C 9 ) heteroaralkyl, ((C 1 -C 8 ) alkyl) x _ 3 - (C 3 - C 8 ) cycloalkyl, ((-C-C 8 ) alkyl) ! _ 3 - (C 6 -C 18 ) aryl, ((d-Cg) -
  • R 1 and R 3 and / or R 2 and R 4 form a ring via a (C 2 -C 8 ) alkylene unit and the use of the compounds of the formula I prepared by such a process
  • diketopiperazines e.g. cyclo [Pro-His] are also pharmacologically active (US 5418218). Structures derived from diketopiperazines are under development as pharmaceuticals (e.g. US 5932579) or are already in use (e.g. Dihydroergotoxin, A. Stoll, Helv. Chim. Acta 26, 2070 (1943), DOS 2802113). Another application is the use as drug delivery systems (WO 9610396, WO 9609813, US 5503852, WO 9318754).
  • diketopiperazines can be used as chiral catalysts, e.g. for the production of chiral cyanohydrins (. North, Synlett, 1993, 807) or as starting materials for the enantioselective production of amino acids (U. Schöllkopf, Tetrahedron 39, 2085 (1983)).
  • esters are only prepared from the dipeptides or an amino acid ester has to be used for the preparation of the dipeptides
  • an additional process step is required.
  • Some 2,5-diketopiperazines can also be obtained by heating the dipeptides in water to temperatures> 100 ° C. (S. Steinberg, Science 213, 544 (1981)).
  • diketopiperazines are relatively easily hydrolysed, complete conversion cannot be obtained with this method. Rather, there is an equilibrium between the diketopiperazine and the two dipeptides.
  • the object was therefore to provide a further process for the preparation of 2,5-diketopiperazines which allows the desired compounds to be made available in good purity and in sufficient yield.
  • the process should be applicable on an industrial scale, i.e. the 2, 5-diketopiperazines should be able to be generated in the most economically and ecologically advantageous manner possible.
  • Claims 2 to 6 represent preferred embodiments of the method according to the invention.
  • Claims 7 to 10 protect special 2,5-diketopiperazines and their precursors, the dipeptides.
  • Claims 11 and 12 are directed to preferred uses.
  • R 1 , R 2 independently of one another are H, (C ⁇ -C 8 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (dC 8 ) alkoxy, ( C 3 -C 8 cycloalkyl, (C 6 -C 18 ) aryl, (C 7 -C 19 ) aralkyl, (C 3 -C ⁇ 8 ) heteroaryl, (C 4 -C ⁇ 9 ) heteroaralkyl, ( (C ⁇ -C 8 ) -alkyl) 3_ 3 - (C 3 - C 8 ) -cycloalkyl, ((d-C ⁇ ) -alkyl) ! _ 3 - (C 6 -C 8 ) aryl, ((dC 8 ) alkyl) ⁇ _3- (C -C 8 ) heteroaryl, or the side chain residue of an ⁇ -amino acid,
  • R 3, R 4 are independently H, (C ⁇ -C8) alkyl, (C 2 -C 8) alkenyl, (C 2 -C 8) -alkynyl, (C ⁇ -C8) -acyl, ( C 3 -C 8 ) cycloalkyl, (C 6 -C 8 ) aryl, (C 7 -C 9 ) aralkyl, (C 3 -C 8 ) heteroaryl, (CC 19 ) heteroaralkyl, ((C ⁇ - C 8 ) alkyl) 3 - (C 3 - C 8 ) cycloalkyl, ((C 8 -C 8 ) alkyl)!
  • solvents which are capable of removing the water in sufficient quantities from the reaction mixtures at elevated temperatures are suitable as solvents.
  • Particularly preferred are solvents which form a low-boiling azeotrope with water, such as acetonitrile, allyl alcohol, benzene, benzyl alcohol, n-butanol, 2-butanol, tert. -Butanol, butyl acetate, carbon tetrachloride, chlorobenzene,
  • the invention is concerned with 2,5-diketopiperazines of the general formula III,
  • R 5 represents H or trifluoromethyl.
  • (S, S) configuration of this compound is preferred.
  • R 5 is H or trifluoromethyl.
  • the (S, S) configuration of this compound is also preferred.
  • III and IV are preferably used for the production of cyclo [Lys-Lys].
  • the compounds of the formula I according to the invention can be used in the synthesis of bioactive compounds.
  • the (Ci-C ⁇ ) alkyl is to be regarded as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl together with all binding isomers. These can be substituted one or more times with (C I -C B ) alkoxy, (-CC 8 ) haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C 8 ) - alkyl.
  • (C 2 -C 8) alkenyl is as above meant with the exception of methyl illustrated (C ⁇ -C 8) -alkyl radical, which has at least one double bond.
  • alkynyl is as above meant with the exception of methyl illustrated (C ⁇ -C 8) -alkyl radical, which has at least one triple bond.
  • cycloalkyl refers to cyclopropyl, cyclobutane tyl, cyclopentyl, cyclohexyl or cycloheptyl radicals etc. These can be with one or more halogens and / or N-, 0-, P-, substituted S-containing radicals and / or have N, 0-, P, S atom-containing radicals in the ring, such as. B. 1-, 2-, 3-, 4-piperidyl, 1-, 2-, 3-pyrrolidinyl, 2-, 3- tetrahydrofuryl, 2-, 3-, 4-morpholinyl. These can also be substituted one or more times with (Ci-Cg) alkoxy, (-C-C 8 ) haloalkyl, OH, Cl, NH 2 , N0 2 .
  • a (C ⁇ -cis) aryl radical is understood to mean an aromatic radical having 6 to 18 carbon atoms.
  • these include compounds such as phenyl, naphthyl, anthryl, phenane thryl, biphenyl residues. This can be substituted one or more times with (Cx-Cs) -alkoxy, (-C-C 8 ) -haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C-C 8 ) -alkyl.
  • a (C 7 -C 19 ) aralkyl radical is a (C ⁇ -Cis) aryl radical bonded to the molecule via a (CC 8 ) alkyl radical.
  • (Ci-Cg) alkoxy is a (C ⁇ -C 8 ) alkyl radical bonded to the molecule under consideration via an oxygen atom.
  • (-C-C 8 ) haloalkyl is a substituted with one or more halogen atoms (-C-C 8 ) alkyl radical.
  • a (C 3 -Ci8) heteroaryl radical denotes a five-, six- or seven-membered aromatic ring system composed of 3 to 18 carbon atoms, which heteroatoms such as, for. B. has nitrogen, oxygen or sulfur in the ring.
  • heteroaromatics are in particular radicals, such as 1-, 2-, 3-furyl, such as 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-, 5-imidazolyl, acridinyl, quinolinyl, phenanthridinyl, 2-, 4-, 5-, 6-pyrimidinyl.
  • radicals such as 1-, 2-, 3-furyl, such as 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-, 5-imidazolyl, acridinyl, quinolinyl, phenanthridinyl, 2-, 4-, 5-, 6-pyrimidinyl.
  • a (C -C 9 ) heteroaralkyl is understood to mean a heteroaromatic system corresponding to the (C 7 -C 9 ) aralkyl radical.
  • (-C-C 8 ) alkylene unit is a (dC 8 ) -
  • alkyl radical which is bonded to the molecule in question via two of its C atoms. This can be substituted one or more times with (C ⁇ -C 8 ) alkoxy, (C ⁇ -C 8 ) haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C-C 8 ) alkyl.
  • a side chain residue of an ⁇ -amino acid is understood to mean the variable residue on the ⁇ -C atom of glycine as the basic amino acid.
  • Natural ⁇ -amino acids are described, for example, in Bayer-Walter, Textbook of Organic Chemistry, S. Hirzel Verlag, Stuttgart, 22nd Edition, pp. 822ff.
  • Preferred unnatural ⁇ -amino acids are those from DE 19903268.8.
  • the side chain remnants can be derived from those shown there.
  • Configuration of the individual chiral centers, axes or planes can be achieved, that is, all possible diastereomers, as well as all optical isomers (enantiomers) included.
  • enantiomerically enriched is understood to mean the proportion of an enantiomer in a mixture with its optical antipode in a range from> 50% and ⁇ 100%.
  • Example la 100 ml of the aqueous dipeptide solution used in Example la were adjusted to pH 4.0 and reacted analogously to Example la. After heating for 1 hour, the ratio was DKP. Dipeptide 99: 1.
  • Example la 100 ml of the aqueous dipeptide solution used in Example la were adjusted to pH 4.0 and heated to boiling.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a method for producing 2,5-diketopiperazines of general formula (I) by heating dipeptides of general formula (II) in an organic solvent while removing water by distillation. The invention also relates to novel 2,5-diketopiperazines, to dipeptides and to the use thereof.

Description

VERFAHREN ZUR HERSTELLUNG VON 2 , 5-DIKETOPIPERAZINEN, 2 , 5-DIKETOPIPERAZINE, DIPEPTIDE UND DEREN VERWENDUNGMETHOD FOR PRODUCING 2, 5-DIKETOPIPERAZINES, 2, 5-DIKETOPIPERAZINE, DIPEPTIDES AND THE USE THEREOF
Die vorliegende Erfindung bezieht sich auf ein Verfahren zur Herstellung von 2 , 5-Diketopiperazinen der allgemeinen 5 Formel I,The present invention relates to a process for the preparation of 2, 5-diketopiperazines of the general 5 formula I,
in der R1, R2 unabhängig voneinander stehen für H, (Cι-C8)- Alkyl, (C2-C8)-Alkenyl, (C2-C8) -Alkinyl, (Cι-C8) -Alkoxy, (C3- 0 C8)-Cycloalkyl, (C6-Cι8) -Aryl, ,(C7-Cι9) -Aralkyl, (C3-Cι8)- Heteroaryl, (C-C19) -Heteroaralkyl, ( (Cι-C8) -Alkyl) ι_3- (C3- C8)-Cycloalkyl, ( (d-C8) -Alkyl) ι_3- (C6-C18) -Aryl, ( (Cι-C8) - Alkyl) !_3- (C3-Cχ8) -Heteroaryl, oder den Seitenkettenrest einer α-Aminosäure, 5 R3, R4 unabhängig voneinander stehen für H, (Cι-C8) -Alkyl, (C2-C8)-Alkenyl, (C2-C8) -Alkinyl, (Cι-C8) -Acyl, (C3-C8)- Cycloalkyl, (C6-C18) -Aryl, (C7-C19) -Aralkyl, (C3-C18)- Heteroaryl, (C4-Cι9) -Heteroaralkyl, ( (Cι-C8) -Alkyl) x_3- (C3- C8)-Cycloalkyl, ( (Cι-C8) -Alkyl) !_3- (C6-C18) -Aryl, ((d-Cg)- 0 Alkyl) ι-3-(C3-Cι8) -Heteroaryl, oderalkyl, (C 2 -C 8) alkenyl, (C 2 -C 8) -alkynyl, (Cι-C8) alkoxy, - independently in which R 1, R 2 from each other, (Cι-C 8) are H, , (C 3 - C 8 ) cycloalkyl, (C 6 -C 8 ) aryl,, (C 7 -C 9 ) aralkyl, (C 3 -C 8 ) heteroaryl, (CC 19 ) heteroaralkyl, ((-C-C 8 ) alkyl) ι_ 3 - (C 3 - C 8 ) cycloalkyl, ((dC 8 ) alkyl) ι_ 3 - (C 6 -C 18 ) aryl, ((Cι-C 8 ) - Alkyl)! _ 3 - (C 3 -Cχ 8 ) heteroaryl, or the side chain residue of an α-amino acid, 5 R 3 , R 4 independently of one another represent H, (-C-C 8 ) -alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (-C-C 8 ) acyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 18 ) aryl, (C 7 - C 19 ) aralkyl, (C 3 -C 18 ) heteroaryl, (C 4 -C 9 ) heteroaralkyl, ((C 1 -C 8 ) alkyl) x _ 3 - (C 3 - C 8 ) cycloalkyl, ((-C-C 8 ) alkyl) ! _ 3 - (C 6 -C 18 ) aryl, ((d-Cg) - 0 alkyl) ι-3- (C 3 -Cι 8 ) heteroaryl, or
R1 und R3 und/oder R2 und R4 bilden über eine (C2-C8)- Alkylen-Einheit einen Ring sowie die Verwendung der durch ein solches Verfahren hergestellten Verbindungen der Formel I.R 1 and R 3 and / or R 2 and R 4 form a ring via a (C 2 -C 8 ) alkylene unit and the use of the compounds of the formula I prepared by such a process
5 Ein weiterer Aspekt der Erfindung beschäftigt sich mit speziellen 2, 5-Diketopiperazinen, Dipeptiden und deren Verwendung. 2, 5-Diketopiperazine, d.h. cyclische Dipeptide, sind eine in der Natur weitverbreitete Substanzklasse (F.T. Witiak, Y. ei, Prog. Drug. Res.'35, 249 (1990)). In den meisten Fällen entstehen sie durch Abbau von Proteinen und sind in vielen Lebensmitteln, wie z.B. Bier (M. Gautschiet, J.5 Another aspect of the invention is concerned with special 2,5-diketopiperazines, dipeptides and their use. 2, 5-Diketopiperazines, ie cyclic dipeptides, are a class of substances that are widespread in nature (FT Witiak, Y.ei, Prog. Drug. Res. 35, 249 (1990)). In most cases, they arise from the breakdown of proteins and are found in many foods, such as beer (M. Gautschiet, J.
Agri. Food Chem. 45, 3183 (1997)) als Geschmackstoffe enthalten. Eine Reihe von Diketopiperazinen, wie z.B. cy- clo[Pro-His] sind darüber hinaus pharmakologisch wirksam (US 5418218). Von Diketopiperazinen abgeleitete Strukturen sind als Pharmazeutika in Entwicklung (z.B. US 5932579) bzw. schon in der Anwendung (z.B. Dihydroergotoxin, A. Stoll, Helv. Chim. Acta 26, 2070 (1943), DOS 2802113). Eine weitere Anwendung besteht in der Verwendung als Drug Deli- very Systems (WO 9610396, WO 9609813, US 5503852, WO 9318754).Agri. Food Chem. 45, 3183 (1997)) as flavorings. A number of diketopiperazines, e.g. cyclo [Pro-His] are also pharmacologically active (US 5418218). Structures derived from diketopiperazines are under development as pharmaceuticals (e.g. US 5932579) or are already in use (e.g. Dihydroergotoxin, A. Stoll, Helv. Chim. Acta 26, 2070 (1943), DOS 2802113). Another application is the use as drug delivery systems (WO 9610396, WO 9609813, US 5503852, WO 9318754).
Weiterhin können Diketopiperazine als chirale Katalysatoren, z.B. zur Herstellung chiraler Cyanhydrine ( . North, Synlett, 1993, 807) oder als Edukte zur enantioselektiven Herstellung von Aminosäuren (U. Schöllkopf, Tetrahedron 39, 2085 (1983)) dienen.Furthermore, diketopiperazines can be used as chiral catalysts, e.g. for the production of chiral cyanohydrins (. North, Synlett, 1993, 807) or as starting materials for the enantioselective production of amino acids (U. Schöllkopf, Tetrahedron 39, 2085 (1983)).
Die gebräuchlichste Methode zur Herstellung von 2,5- Diketopiperazinen besteht darin, Ester der entsprechenden Dipeptide aus den Salzen freizusetzen und ggf. zu erhitzen (E. Fischer, Chem. Ber. 34, 2893 (1903)). Da die freien Ester jedoch basisch sind und andererseits bekannt ist, daß Diketopiperazine leichter racemisieren als die entsprechenden Dipeptide bzw. Aminosäuren, ist bei dieser Methode oft mit einer teilweisen Race isierung zu rechnen. Dies kann weitgehend vermieden werden, indem bei der Cyclisierung der Ester Essigsäure zugesetzt wird (T. Ueda, Bull. Chem. Soc. Jpn., 50 566 (1983). Dennoch hat diese Methode den Nachteil, daß die Ester erst aus den Dipeptiden hergestellt werden müssen oder für die Herstellung der Dipeptide ein Aminosäureester eingesetzt werden muß. In beiden Fällen ist ein zusätzlicher Verfahrensschritt erforderlich. Einige 2, 5-Diketopiperazine können auch durch Erhitzen der Dipeptide in Wasser auf Temperaturen >100°C erhalten werden (S. Steinberg, Science 213, 544 (1981)). Da jedoch Diketopiperazine relativ leicht hydrolysiert werden, ist bei die- ser Methode kein vollständiger Umsatz zu erhalten. Vielmehr stellt sich ein Gleichgewicht zwischen dem Diketopiperazin und den beiden Dipeptiden ein.The most common method for producing 2,5-diketopiperazines is to release esters of the corresponding dipeptides from the salts and, if necessary, to heat them (E. Fischer, Chem. Ber. 34, 2893 (1903)). However, since the free esters are basic and, on the other hand, it is known that diketopiperazines racemize more easily than the corresponding dipeptides or amino acids, a partial race isation can be expected with this method. This can be largely avoided by adding acetic acid during the cyclization of the esters (T. Ueda, Bull. Chem. Soc. Jpn., 50 566 (1983). Nevertheless, this method has the disadvantage that the esters are only prepared from the dipeptides or an amino acid ester has to be used for the preparation of the dipeptides In both cases an additional process step is required. Some 2,5-diketopiperazines can also be obtained by heating the dipeptides in water to temperatures> 100 ° C. (S. Steinberg, Science 213, 544 (1981)). However, since diketopiperazines are relatively easily hydrolysed, complete conversion cannot be obtained with this method. Rather, there is an equilibrium between the diketopiperazine and the two dipeptides.
Aufgabe war deshalb eine weiteres Verfahren zur Herstellung von 2, 5-Diketopiperazinen zur Verfügung zu stellen, welches es gestattet die gewünschten Verbindungen in guter Reinheit und ausreichender Ausbeute zur Verfügung zu stellen. Insbesondere sollte das Verfahren im technischen Maßstab anwendbar sein, d.h. die 2, 5-Diketopiperazinen sollten in möglichst ökonomisch und ökologisch vorteilhafter Weise gene- riert werden können.The object was therefore to provide a further process for the preparation of 2,5-diketopiperazines which allows the desired compounds to be made available in good purity and in sufficient yield. In particular, the process should be applicable on an industrial scale, i.e. the 2, 5-diketopiperazines should be able to be generated in the most economically and ecologically advantageous manner possible.
Diese Aufgabe wird durch ein Verfahren gemäß Anspruch 1 gelöst. Die Ansprüche 2 bis 6 stellen bevorzugte Ausgestaltungen des erfindungsgemäßen Verfahrens dar. Ansprüche 7 bis 10 schützen spezielle 2, 5-Diketopiperazinen und deren Vorstufen, die Dipeptide. Ansprüche 11 und 12 sind auf bevorzugte Verwendungen gerichtet.This object is achieved by a method according to claim 1. Claims 2 to 6 represent preferred embodiments of the method according to the invention. Claims 7 to 10 protect special 2,5-diketopiperazines and their precursors, the dipeptides. Claims 11 and 12 are directed to preferred uses.
Dadurch, daß man bei einem Verfahren zur Herstellung von 2, 5-Diketopiperazinen der allgemeinen Formel I,The fact that in a process for the preparation of 2,5-diketopiperazines of the general formula I,
in der R1, R2 unabhängig voneinander stehen für H, (Cχ-C8 ) - Alkyl , (C2-C8 ) -Alkenyl , (C2-C8) -Alkinyl , (d-C8) -Alkoxy, (C3- C8 ) -Cycloalkyl, (C6-C18) -Aryl, (C7-C19) -Aralkyl , (C3-Cι8) - Heteroaryl , (C4-Cι9) -Heteroaralkyl , ( (Cι-C8) -Alkyl ) χ_3- (C3- C8)-Cycloalkyl, ( (d-Cβ) -Alkyl) !_3- (C6-Cι8) -Aryl, ((d-C8)- Alkyl) ι_3- (C-Cι8) -Heteroaryl, oder den Seitenkettenrest einer α-Aminosäure,in which R 1 , R 2 independently of one another are H, (Cχ-C 8 ) alkyl, (C 2 -C 8 ) alkenyl, (C 2 -C 8 ) alkynyl, (dC 8 ) alkoxy, ( C 3 -C 8 cycloalkyl, (C 6 -C 18 ) aryl, (C 7 -C 19 ) aralkyl, (C 3 -Cι 8 ) heteroaryl, (C 4 -Cι 9 ) heteroaralkyl, ( (Cι-C 8 ) -alkyl) 3_ 3 - (C 3 - C 8 ) -cycloalkyl, ((d-Cβ) -alkyl) ! _ 3 - (C 6 -C 8 ) aryl, ((dC 8 ) alkyl) ι_3- (C -C 8 ) heteroaryl, or the side chain residue of an α-amino acid,
R3, R4 unabhängig voneinander stehen für H, (Cι-C8) -Alkyl, (C2-C8)-Alkenyl, (C2-C8) -Alkinyl, (Cι-C8) -Acyl, (C3-C8)- Cycloalkyl, (C6-Cι8) -Aryl, (C7-Cι9) -Aralkyl, (C3-Cι8)- Heteroaryl, (C-C19) -Heteroaralkyl, ( (Cι-C8) -Alkyl) ι_3- (C3- C8)-Cycloalkyl, ( (Cι-C8) -Alkyl) !_3- (C6-Cι8) -Aryl, ((Cι-C8)- Alkyl) ι_3- (C3-Cι8) -Heteroaryl, oder R1 und R3 und/oder R2 und R4 bilden über eine (C2-C8)- Alkylen-Einheit einen Ring, Dipeptide der allgemeinen Formel IIR 3, R 4 are independently H, (Cι-C8) alkyl, (C 2 -C 8) alkenyl, (C 2 -C 8) -alkynyl, (Cι-C8) -acyl, ( C 3 -C 8 ) cycloalkyl, (C 6 -C 8 ) aryl, (C 7 -C 9 ) aralkyl, (C 3 -C 8 ) heteroaryl, (CC 19 ) heteroaralkyl, ((Cι- C 8 ) alkyl) 3 - (C 3 - C 8 ) cycloalkyl, ((C 8 -C 8 ) alkyl)! _ 3 - (C 6 -C 8 ) aryl, ((C 8 C) - Alkyl) 3 - (C 3 -C 8 ) heteroaryl, or R 1 and R 3 and / or R 2 and R 4 form a ring via a (C 2 -C 8 ) alkylene unit, dipeptides of the general type Formula II
in der R1, R2, R3, R4 die oben angegebene Bedeutung besitzen, in einem organischen Lösungsmittel unter destillativer Entfernung von Wasser erhitzt, gelangt man überraschend einfach in einem im technischen Maßstab vorteilhaft durchzu- führenden Prozeß und in guten Ausbeuten und hoher Reinheit zu den gewünschten 2, 5-Diketopiperazinen. Zum Teil erhält man die Piperazine in bis zu 70% Kristallisationsausbeute mit einer Reinheit von >99% per HPLC nach einer Kristallisation, insbesondere hoch enantiomerenangereichert .in which R 1 , R 2 , R 3 , R 4 have the meaning given above, heated in an organic solvent with removal of water by distillation, is surprisingly easy to achieve in a process which can advantageously be carried out on an industrial scale and in good yields and high Purity to the desired 2, 5-diketopiperazines. Some of the piperazines are obtained in up to 70% crystallization yield with a purity of> 99% by HPLC after crystallization, in particular highly enantiomerically enriched.
Als Lösungsmittel kommen im Prinzip alle organischen Lösungsmittel in Betracht, die befähigt sind, in ausreichender Menge das Wasser unter erhöhten Temperaturen aus dem Reaktionsgemische zu entfernen. Besonders bevorzugt sind Lösungsmittel, die mit Wasser ein niedrig siedendes Azeotrop bilden, wie z.B. Acetonitril, Allylalkohol, Benzol, Benzylalkohol, n-Butanol, 2-Butanol, tert . -Butanol, Essigsäurebutylester, Kohlenstofftetrachlorid, Chlorbenzol, In principle, all organic solvents which are capable of removing the water in sufficient quantities from the reaction mixtures at elevated temperatures are suitable as solvents. Particularly preferred are solvents which form a low-boiling azeotrope with water, such as acetonitrile, allyl alcohol, benzene, benzyl alcohol, n-butanol, 2-butanol, tert. -Butanol, butyl acetate, carbon tetrachloride, chlorobenzene,
Behandeln mit Wasser gereinigt werden, wobei alle Salze und ggf. nicht umgesetzte Dipetide bzw. Aminosäuren entfernt werden können. In Fällen in denen die 2, 5-Diketopiperazine in organischen, nicht wasssermischbaren Lösungsmitteln löslich sind, kann diese Reinigung sogar durch Extraktion mit Wasser erfolgen.Treat with water, whereby all salts and possibly unreacted dipetides or amino acids can be removed. In cases where the 2, 5-diketopiperazines are soluble in organic, water-immiscible solvents, this cleaning can even be carried out by extraction with water.
Die Vorteile des erfindungsgemäßen Verfahrens werden eindrucksvoll durch ein Vergleichsbeispiel belegt. Während die Cyclisierung einer wäßrigen L-Phenylalanyl-L-prolin-Lösung bei pH 4 mit n-Butanol nach einer Stunden bereits 99% Umsatz liefert, erhält,man durch Erhitzen der gleichen Lösung ohne n-Butanol auf Rückflußtemperatur nach 4 Stunden lediglich 19 % Umsatz. Nach 20 Stunden bei dieser Temperatur ist das L-Phenylalanyl-L-prolin zwar nicht mehr nachweisbar, neben 70 % des 2, 5-Diketopiperazins erhält man aber 30 % des inversen Dipeptides L-Prolyl-L-phenylalanin. Dies wird beim erfindungsgemäßen Verfahren nicht erhalten.The advantages of the method according to the invention are impressively demonstrated by a comparative example. While the cyclization of an aqueous L-phenylalanyl-L-proline solution at pH 4 with n-butanol already gives 99% conversion after one hour, only 19% is obtained by heating the same solution without n-butanol to the reflux temperature after 4 hours. Sales. After 20 hours at this temperature, the L-phenylalanyl-L-prolin is no longer detectable, but in addition to 70% of the 2,5-diketopiperazine, 30% of the inverse dipeptide L-prolyl-L-phenylalanine is obtained. This is not obtained in the method according to the invention.
In einer weiteren Ausgestaltung beschäftigt sich die Erfindung mit 2, 5-Diketopiperazine der allgemeinen Formel III,In a further embodiment, the invention is concerned with 2,5-diketopiperazines of the general formula III,
in der R5 für H oder Trifluormethyl steht. Bevorzugt ist die (S, S) -Konfiguration dieser Verbindung.in which R 5 represents H or trifluoromethyl. The (S, S) configuration of this compound is preferred.
Außerdem ist die Erfindung auf Dipeptide der Formel (IV) ,In addition, the invention relates to dipeptides of the formula (IV)
gerichtet, in der R5 für H oder Trifluormethyl steht. Ebenfalls bevorzugt ist die (S, S) -Konfiguration dieser Verbindung. III und IV werden vorzugsweise zur Herstellung von cyclo [Lys-Lys] verwendet. Die erfindungsgemäßen Verbindungen der Formel I können in der Synthese- bioaktiver Verbindungen Verwendung finden. directed in which R 5 is H or trifluoromethyl. The (S, S) configuration of this compound is also preferred. III and IV are preferably used for the production of cyclo [Lys-Lys]. The compounds of the formula I according to the invention can be used in the synthesis of bioactive compounds.
Als (Ci-Cβ) -Alkyl sind anzusehen Methyl, Ethyl, n-Propyl, Isopropyl, n-Butyl, Isobutyl, sec-Butyl, tert-Butyl, Pen- tyl, Hexyl, Heptyl oder Octyl samt aller Bindungsisomeren. Diese können einfach oder mehrfach mit (CI-CB) -Alkoxy, (Cι-C8)-Haloalkyl, OH, Halogen, NH2, N02, SH, S-(Cι-C8)- Alkyl substituiert sein.The (Ci-Cβ) alkyl is to be regarded as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl together with all binding isomers. These can be substituted one or more times with (C I -C B ) alkoxy, (-CC 8 ) haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C 8 ) - alkyl.
Als (C2-C8) -Alkenyl ist mit Ausnahme von Methyl ein wie oben dargestellter (Cι-C8) -Alkyl-Rest zu verstehen, der mindestens eine Doppelbindung aufweist.(C 2 -C 8) alkenyl is as above meant with the exception of methyl illustrated (Cι-C 8) -alkyl radical, which has at least one double bond.
Unter (C2-C8) -Alkinyl ist mit Ausnahme von Methyl ein wie oben dargestellter (Cι-C8) -Alkyl-Rest zu verstehen, der mindestens eine Dreifachbindung aufweist.As (C 2 -C 8) alkynyl is as above meant with the exception of methyl illustrated (Cι-C 8) -alkyl radical, which has at least one triple bond.
Unter (Cι-C8)-Acyl versteht man einen über eine C=0- Funktion ans Molekül gebundenen (Cι-C8) -Alkyl-Rest .(C 1 -C 8 ) acyl is understood to mean a (C 1 -C 8 ) alkyl radical bonded to the molecule via a C = 0 function.
Unter (Cß-Cs) -Cycloalkyl versteht man Cyclopropyl, Cyclobu- tyl, Cyclopentyl, Cyclohexyl bzw. Cycloheptylreste etc. Diese können mit einem oder mehreren Halogenen und/oder N-, 0-, P-, S-atomhaltige Reste substituiert sein und/oder N-, 0-, P-, S-atomhaltige Reste im Ring aufweisen, wie z. B. 1-, 2-, 3-, 4-Piperidyl, 1-, 2-, 3-Pyrrolidinyl, 2-, 3- Tetrahydrofuryl, 2-, 3-, 4-Morpholinyl. Diese können auch einfach oder mehrfach mit (Ci-Cg) -Alkoxy, (Cι-C8) -Haloalkyl, OH, Cl, NH2, N02 substituiert sein.Among (C ß -Cs) cycloalkyl refers to cyclopropyl, cyclobutane tyl, cyclopentyl, cyclohexyl or cycloheptyl radicals etc. These can be with one or more halogens and / or N-, 0-, P-, substituted S-containing radicals and / or have N, 0-, P, S atom-containing radicals in the ring, such as. B. 1-, 2-, 3-, 4-piperidyl, 1-, 2-, 3-pyrrolidinyl, 2-, 3- tetrahydrofuryl, 2-, 3-, 4-morpholinyl. These can also be substituted one or more times with (Ci-Cg) alkoxy, (-C-C 8 ) haloalkyl, OH, Cl, NH 2 , N0 2 .
Unter einem (Cβ-Cis) -Arylrest wird ein aromatischer Rest mit 6 bis 18 C-Atomen verstanden. Insbesondere zählen hierzu Verbindungen wie Phenyl-, Naphthyl-, Anthryl-, Phenan- thryl-, Biphenylreste. Dieser kann einfach oder mehrfach mit (Cx-Cs) -Alkoxy, (Cι-C8) -Haloalkyl, OH, Halogen, NH2, N02, SH, S-(Cι-C8) -Alkyl substituiert sein.A (Cβ-cis) aryl radical is understood to mean an aromatic radical having 6 to 18 carbon atoms. In particular, these include compounds such as phenyl, naphthyl, anthryl, phenane thryl, biphenyl residues. This can be substituted one or more times with (Cx-Cs) -alkoxy, (-C-C 8 ) -haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C-C 8 ) -alkyl.
Ein (C7-C19) -Aralkylrest ist ein über einen (C-C8)- Alkylrest an das Molekül gebundener (Cβ-Cis) -Arylrest .A (C 7 -C 19 ) aralkyl radical is a (Cβ-Cis) aryl radical bonded to the molecule via a (CC 8 ) alkyl radical.
(Ci-Cg) -Alkoxy ist ein über ein Sauerstoffatom an das betrachtete Molekül gebundener (Cι-C8) -Alkyl-Rest .(Ci-Cg) alkoxy is a (Cι-C 8 ) alkyl radical bonded to the molecule under consideration via an oxygen atom.
(Cι-C8) -Haloalkyl ist ein mit einem oder mehreren Halogenatomen substituierter (Cι-C8) -Alkyl-Rest .(-C-C 8 ) haloalkyl is a substituted with one or more halogen atoms (-C-C 8 ) alkyl radical.
Ein (C3-Ci8) -Heteroarylrest bezeichnet im Rahmen der Erfindung ein fünf-, sechs- oder siebengliedriges aromatisches Ringsystem aus 3 bis 18 C-Atomen, welches Heteroatome wie z. B. Stickstoff, Sauerstoff oder Schwefel im Ring aufweist. Als solche Heteroaromaten werden insbesondere Rest angesehen, wie 1-, 2-, 3-Furyl, wie 1-, 2-, 3-Pyrrolyl, 1-,2-,3-Thienyl, 2-, 3-, 4-Pyridyl, 2-, 3-, 4-, 5-, 6-, 7-Indolyl, 3-, 4-, 5-Pyrazolyl, 2-, 4-, 5-Imidazolyl, Acri- dinyl, Chinolinyl, Phenanthridinyl, 2-, 4-, 5-, 6-Pyrimidinyl. Dieses kann einfach oder mehrfach mit (Cι-C8) -Alkoxy, (Cι-C8) -Haloalkyl, OH, Halogen, NH2, N02, SH, S- (Cι-C8) -Alkyl substituiert sein.In the context of the invention, a (C 3 -Ci8) heteroaryl radical denotes a five-, six- or seven-membered aromatic ring system composed of 3 to 18 carbon atoms, which heteroatoms such as, for. B. has nitrogen, oxygen or sulfur in the ring. Such heteroaromatics are in particular radicals, such as 1-, 2-, 3-furyl, such as 1-, 2-, 3-pyrrolyl, 1-, 2-, 3-thienyl, 2-, 3-, 4-pyridyl, 2-, 3-, 4-, 5-, 6-, 7-indolyl, 3-, 4-, 5-pyrazolyl, 2-, 4-, 5-imidazolyl, acridinyl, quinolinyl, phenanthridinyl, 2-, 4-, 5-, 6-pyrimidinyl. This can be substituted one or more times with (-CC 8 ) alkoxy, (-CC 8 ) haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C 8 ) -alkyl.
Unter einem (C-Cι9) -Heteroaralkyl wird ein dem (C7-Cι9) -Aralkylrest entsprechendes heteroaromatisches System verstanden.A (C -C 9 ) heteroaralkyl is understood to mean a heteroaromatic system corresponding to the (C 7 -C 9 ) aralkyl radical.
Unter dem Begriff (Cι-C8) -Alkylen-Einheit ist ein (d-C8)-Under the term (-C-C 8 ) alkylene unit is a (dC 8 ) -
Alkylrest zu verstehen, der über zwei seiner C-Atome an das betreffende Molekül gebunden ist. Dieser kann einfach oder mehrfach mit (Cχ-C8) -Alkoxy, (Cχ-C8) -Haloalkyl, OH, Halogen, NH2, N02, SH, S- (Cι-C8) -Alkyl substituiert sein.To understand alkyl radical which is bonded to the molecule in question via two of its C atoms. This can be substituted one or more times with (Cχ-C 8 ) alkoxy, (Cχ-C 8 ) haloalkyl, OH, halogen, NH 2 , NO 2 , SH, S- (-C-C 8 ) alkyl.
Als Halogene kommen Fluor, Chlor, Brom und lod in Frage. Unter einem Seitenkettenrest einer α-Aminosäure wird der veränderliche Rest am α-C-Atom von Glycin als Basisaminosäure verstanden. Natürliche α-Aminosäure sind beispielsweise in Bayer-Walter, Lehrbuch der organischen Che- mie, S. Hirzel Verlag, Stuttgart, 22. Auflage, S. 822ff dargestellt. Bevorzugte unnatürliche α-Aminosäuren sind solche aus der DE 19903268.8. Die Seitenkettenreste können von den dort dargestellten abgeleitet werden.Halogen, fluorine, chlorine, bromine and iodine are suitable. A side chain residue of an α-amino acid is understood to mean the variable residue on the α-C atom of glycine as the basic amino acid. Natural α-amino acids are described, for example, in Bayer-Walter, Textbook of Organic Chemistry, S. Hirzel Verlag, Stuttgart, 22nd Edition, pp. 822ff. Preferred unnatural α-amino acids are those from DE 19903268.8. The side chain remnants can be derived from those shown there.
Die dargestellten chemischen Strukuren beziehen sich auf alle möglichen Stereoisomeren, die durch Abänderung derThe chemical structures shown relate to all possible stereoisomers that are created by modifying the
Konfiguration der einzelnen chiralen Zentren, Achsen oder Ebenen erreicht werden können, also alle möglichen Diaste- reomere, sowie alle darunter fallende optische Isomere (En- antiomere) .Configuration of the individual chiral centers, axes or planes can be achieved, that is, all possible diastereomers, as well as all optical isomers (enantiomers) included.
Unter dem Begriff enantiomerenangereichert wird im Rahmen der Erfindung der Anteil eines Enantiomers im Gemisch mit seiner optischen Antipode in einem Bereich von >50 % und <100 % verstanden. In the context of the invention, the term enantiomerically enriched is understood to mean the proportion of an enantiomer in a mixture with its optical antipode in a range from> 50% and <100%.
Beispiele:Examples:
Herstellung von cyclo [L-Phenylalanyl-L-prolyl]Preparation of cyclo [L-phenylalanyl-L-prolyl]
a. Cyclisierung bei pH = 6.4a. Cyclization at pH = 6.4
1940 g einer wäßrigen Lösung von 235 g L-Phenylalanyl-L- prolin, die noch 7 g L-Phenylalanin sowie ca. 300 g Kaliumchlorid enthielt wurde auf pH 6.4 gestellt und i.Vak. bis zu einem dicken Kristallbrei eingeengt. Es wurden dann 1 1 n-Butanol zugegeben und 2 Stunden am Wasserabscheider er- hitzt. Laut HPLC bestand die Mischung dann aus 57 % DKP und 26 % Dipeptid. Nach dem Abkühlen wurden 700 ml Wasser zugegeben und die Phasen getrennt. Die organische Phase wurde nochmals mit 150 ml Wasser gewaschen und i.Vak. eingengt. Das verbleibende' Öl wurde mit MTBE verrührt und der ent- standene Feststoff abfiltriert. Man erhielt 113 g (52 % d.Th.) cyclo [L-Phenylalanyl-L-prolyl] mit einer HPLC- Reinheit >99% und einem [α]D/20 von -105.1° (c=l, n- Butanol) .1940 g of an aqueous solution of 235 g of L-phenylalanyl-L-prolin, which still contained 7 g of L-phenylalanine and about 300 g of potassium chloride, was adjusted to pH 6.4 and i.Vak. concentrated to a thick crystal mash. 1 l of n-butanol was then added and the mixture was heated for 2 hours on a water separator. According to HPLC, the mixture then consisted of 57% DKP and 26% dipeptide. After cooling, 700 ml of water were added and the phases were separated. The organic phase was washed again with 150 ml of water and i.Vac. eingengt. The remaining 'oil was stirred with MTBE and corresponds avowed solid filtered off. This gave 113 g (52% of theory) of cyclo [L-phenylalanyl-L-prolyl] with an HPLC purity> 99% and an [α] D / 20 of -105.1 ° (c = 1, n-butanol ).
b. Cyclisierung bei pH = 4.0b. Cyclization at pH = 4.0
100 ml der in Beispiel la eingesetzten wäßrigen Dipeptidlö- sung wurden auf pH 4.0 gestellt und analog Beispiel la umgesetzt. Nach 1-stündigem Erhitzen betrug das Verhältnis DKP . Dipeptid 99 : 1.100 ml of the aqueous dipeptide solution used in Example la were adjusted to pH 4.0 and reacted analogously to Example la. After heating for 1 hour, the ratio was DKP. Dipeptide 99: 1.
c. Cyclisierung bei pH = 4.0 in Wasserc. Cyclization at pH = 4.0 in water
100 ml der in Beispiel la eingesetzten wäßrigen Dipeptidlö- sung wurden auf pH 4.0 gestellt und zum Sieden erhitzt. Der100 ml of the aqueous dipeptide solution used in Example la were adjusted to pH 4.0 and heated to boiling. The
Verlauf der Reaktion wurde mit HPLC verfolgt. .Das Verhält- nis DKP . Dipeptid betrug nach 2 Stunden 19 : 81 und nach 4 Stunden 39 : 61. Nach 24 Stunden war kein L-Phenylalanyl-L- prolin mehr nachweisbar. Stattdessen wurde das DKP und das L-Prolyl-L-phenylalanin im Verhältnis 69 : 31 detektiert.The course of the reaction was followed by HPLC. .The DKP ratio. Dipeptide was 19:81 after 2 hours and after 4 Hours 39: 61. After 24 hours, no L-phenylalanyl-L-prolin was detectable. Instead, the DKP and the L-prolyl-L-phenylalanine were detected in a ratio of 69:31.
Herstellung von cyclo [L-Valyl-L-prolyl]Preparation of cyclo [L-valyl-L-prolyl]
1740 g einer wäßrigen Lösung von 132 g L-Valyl-L-prolin, die noch ca. 10 g L-Valin sowie ca. 300 g Kaliumchlorid enthielt wurde auf pH 6. 4 gestellt und i.Vak. bis zu einem dicken Kristallbrei eingeengt. Es wurden dann 1 1 n-Butanol zugegeben und 2 Stunden am Wasserabscheider erhitzt. Laut HPLC enthielt die Mischung dann noch 3 % des Dipeptides. Nach dem Abkühlen wurden 800 ml Wasser zugegeben und die Phasen getrennt. Die organische Phase wurde nochmals mit 200 ml Wasser gewaschen und i.Vak. eingengt. Die verblei- bende Kristallsuspension wurde mit Ethylacetat verrührt und der Feststoff abfiltriert. Man erhielt 70,5 g (58 % d.Th.) cyclo [L-Valyl-L-prolyl] mit einer HPLC-Reinheit >99% und einem [α]D/2o von -164.3° (c=l, n-Butanol).1740 g of an aqueous solution of 132 g of L-valyl-L-proline, which still contained about 10 g of L-valine and about 300 g of potassium chloride, was adjusted to pH 6.4 and i.Vak. concentrated to a thick crystal mash. 1 l of n-butanol was then added and the mixture was heated for 2 hours on a water separator. According to HPLC, the mixture then still contained 3% of the dipeptide. After cooling, 800 ml of water were added and the phases were separated. The organic phase was washed again with 200 ml of water and i.Vak. eingengt. The remaining crystal suspension was stirred with ethyl acetate and the solid was filtered off. 70.5 g (58% of theory) of cyclo [L-valyl-L-prolyl] with an HPLC purity> 99% and an [α] D / 2o of -164.3 ° (c = 1, n butanol).
Herstellung von cyclo [L-Leucyl-L-prolyl]Preparation of cyclo [L-leucyl-L-prolyl]
1350 ml einer wäßrigen Lösung von 145 g L-Leucyl-L-prolin, die noch ca. 7 g L-Leucin sowie ca. 225 g Kaliumchlorid enthielt wurde auf pH 4.5 gestellt und i.Vak. bis zu einem dicken Kristallbrei eingeengt. Es wurden dann 1 1 n-Butanol zugegeben und 0.5 Stunden am Wasserabscheider erhitzt. Laut HPLC enthielt die Mischung dann noch 3 % des Dipeptides. Nach dem Abkühlen wurden 500 ml Wasser zugegeben und die Phasen getrennt. Die organische Phase wurde nochmals mit 100 ml Wasser gewaschen und i.Vak. eingengt. Die verblei- bende Kristallsuspension wurde mit Ethylacetat verrührt und der Feststoff abfiltriert. Man erhielt 91,8 g (69 % d.Th.) cyclo [L-Leucyl-L-prolyl] mit einer HPLC-Reinheit >99% und einem [α]D/20 von -137,4° (c=l, n-Butanol). Herstellung von cyclo [L-Isoleucyl-L-prolyl]1350 ml of an aqueous solution of 145 g of L-leucyl-L-proline, which still contained about 7 g of L-leucine and about 225 g of potassium chloride, was adjusted to pH 4.5 and i.Vac. concentrated to a thick crystal mash. 1 l of n-butanol was then added and the mixture was heated for 0.5 hours on a water separator. According to HPLC, the mixture then still contained 3% of the dipeptide. After cooling, 500 ml of water were added and the phases were separated. The organic phase was washed again with 100 ml of water and i.Vac. eingengt. The remaining crystal suspension was stirred with ethyl acetate and the solid was filtered off. 91.8 g (69% of theory) of cyclo [L-leucyl-L-prolyl] with an HPLC purity> 99% and an [α] D / 2 O of -137.4 ° (c = l, n-butanol). Preparation of cyclo [L-isoleucyl-L-prolyl]
2030 g einer wäßrigen Lösung von 199 g L-Isoleucyl-L- prolin, die noch ca. 7 g L-Isoleucin sowie ca. 300 g Kaliumchlorid enthielt wurde auf pH 6.4 gestellt und i.Vak. bis zu einem dicken Kristallbrei eingeengt. Es wurden dann 1 1 n-Butanol zugegeben und 1 Stunden am Wasserabscheider erhitzt. Laut HPLC enthielt die Mischung dann noch 1 % des Dipeptides. Nach dem Abkühlen wurden 500 ml Wasser zugegeben und die Phasen getrennt. Die organische Phase wurde nochmals mit 100 ml Wasser gewaschen und i.Vak. eingengt.2030 g of an aqueous solution of 199 g of L-isoleucyl-L-prolin, which still contained about 7 g of L-isoleucine and about 300 g of potassium chloride, was adjusted to pH 6.4 and i.Vak. concentrated to a thick crystal mash. 1 l of n-butanol was then added and the mixture was heated for 1 hour on a water separator. According to HPLC, the mixture then still contained 1% of the dipeptide. After cooling, 500 ml of water were added and the phases were separated. The organic phase was washed again with 100 ml of water and i.Vac. eingengt.
Die verbleibende Kristallsuspension wurde mit MtBE verrührt und der Feststoff abfiltriert. Man erhielt 126.3g (70 % d.Th.) cyclo [L-Isoleucyl-L-prolyl] mit einer HPLC-Reinheit >99% und einem [α]D/20 von -105.1° (c=l, n-Butanol).The remaining crystal suspension was stirred with MtBE and the solid was filtered off. This gave 126.3 g (70% of theory) of cyclo [L-isoleucyl-L-prolyl] with an HPLC purity> 99% and an [α] D / 20 of -105.1 ° (c = 1, n-butanol ).
Herstellung von cyclo [ε-Trifluoracetyl-L-lysyl-ε- trifluoracetyl-L-lysyl]Preparation of cyclo [ε-trifluoroacetyl-L-lysyl-ε-trifluoroacetyl-L-lysyl]
500 ml einer butanolischen Lösung von 21 g ε- Trifluoracetyl-L-lysyl-ε-trifluoracetyl-L-lysin hydrochlo- rid wurde mit 50%-iger Natronlauge auf pH 6 gestellt und 2 Stunden am Wasserabscheider erhitzt. Nach HPLC-Analyse sind dann 57 % des Dipeptides zum DKP cyclisiert. Der nach Abkühlen ausgefallenen Feststoff wird abfiltriert und getrocknet. Man erhält 8.0 g cyclo [ε-Trifluoracetyl-L-lysyl- ε-trifluoracetyl-L-lysyl] .500 ml of a butanolic solution of 21 g ε-trifluoroacetyl-L-lysyl-ε-trifluoroacetyl-L-lysine hydrochloride was adjusted to pH 6 with 50% sodium hydroxide solution and heated for 2 hours on a water separator. According to HPLC analysis, 57% of the dipeptide is then cyclized to the DKP. The solid which precipitates after cooling is filtered off and dried. 8.0 g of cyclo [ε-trifluoroacetyl-L-lysyl- ε-trifluoroacetyl-L-lysyl] are obtained.
XH-NMR (d6-DMS0) : 1.30 ( , 4H) , 1.48 (m, 4H) , 1.67 (m,4H), 3.17 (m, 4H) , 3.80 (m, 2H) , 8.13 (s, 2H) , 9.43 (s, 2H) . X H NMR (d 6 -DMS0): 1.30 (, 4H), 1.48 (m, 4H), 1.67 (m, 4H), 3.17 (m, 4H), 3.80 (m, 2H), 8.13 (s, 2H ), 9.43 (s, 2H).

Claims

Patentansprüche : Claims:
1. Verfahren zur Herstellung von 2, 5-Diketopiperazinen der allgemeinen Formel I,1. Process for the preparation of 2,5-diketopiperazines of the general formula I,
in der R1, R2 unabhängig voneinander stehen für H, (Cj- C8) -Alkyl, (d-C8)-Alkenyl, (C2-C8) -Alkinyl, (Cx-C8)- Alkoxy, (C3-C8) -Cycloalkyl, (C6-Cι8) -Aryl, (C7-Cι9)- Aralkyl, (C3-Cι8) -Heteroaryl, (C4-Cι9) -Heteroaralkyl, ((d-C8) -Alkyl) 1_3-(C3-C8) -Cycloalkyl, ( (Cι-C8) -Alkyl) 1-3- (C6-Cι8) -Aryl, ( (d-C8) -Alkyl) ι_3- (C3-C18) -Heteroaryl, oder den Seitenkettenrest einer α-Aminosäure, R3, R4 unabhängig voneinander stehen für H, (Cι-C8)- Alkyl, (C2-C8)-Alkenyl, (C2-C8) -Alkinyl, (Cι-C8) -Acyl, (C3-C8) -Cycloalkyl, (C6-C18) -Aryl, (C7-Cι9) -Aralkyl, (C3- Cι8) -Heteroaryl, (C4-C19) -Heteroaralkyl, ((Cι~C8)- Alkyl) 1-3- (C3-C8) -Cycloalkyl, ( (d-C8) -Alkyl) 1-3- (C6-d8) - Aryl, ( (Cι-C8) -Alkyl) 1-3- (C3-Cι8) -Heteroaryl, oder R1 und R3 und/oder R2 und R4 bilden über eine (C2-C8)- Alkylen-Einheit einen Ring, durch Erhitzen von Dipeptiden der allgemeinen Formel IIin which R 1 , R 2 independently of one another are H, (Cj-C 8 ) -alkyl, (dC 8 ) -alkenyl, (C 2 -C 8 ) -alkynyl, (C x -C 8 ) -alkoxy, ( C 3 -C 8 ) cycloalkyl, (C 6 -C 8 ) aryl, (C 7 -C 9 ) aralkyl, (C 3 -C 8 ) heteroaryl, (C 4 -C 9 ) heteroaralkyl, ( (dC 8 ) -alkyl) 1 _ 3 - (C 3 -C 8 ) -cycloalkyl, ((-C-C 8 ) -alkyl) 1-3- (C 6 -Cι 8 ) -aryl, ((dC 8 ) -Alkyl) ι_ 3 - (C 3 -C 18 ) heteroaryl, or the side chain residue of an α-amino acid, R 3 , R 4 independently of one another are H, (-C-C 8 ) - alkyl, (C 2 -C 8 ) Alkenyl, (C 2 -C 8 ) alkynyl, (Cι-C 8 ) acyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 18 ) aryl, (C 7 -Cι 9 ) aralkyl, (C 3 - Cι 8) -heteroaryl, (C4-C19) -heteroaralkyl, ((Cι ~ C 8) - alkyl) 1-3- (C 3 -C 8) cycloalkyl, ((dC 8 ) Alkyl) 1-3- (C 6 -d 8 ) aryl, ((-C 8 -C 8 ) alkyl) 1 - 3 - (C 3 -C 8 ) heteroaryl, or R 1 and R 3 and / or R 2 and R 4 form a ring via a (C 2 -C 8 ) alkylene unit, by heating dipeptides in general Formula II
in der R1, R , R , R4 die oben angegebene Bedeutung be- sitzen, in einem organischen Lösungsmittel unter destillativerin which R 1 , R, R, R 4 have the meaning given above sit in an organic solvent under distillative
Entfernung von Wasser.Removal of water.
2. Verfahren nach Anspruch 1, » dadurch gekennzeichnet, daß man ein organisches Lösungsmittel verwendet, das mit Wasser ein Azeotrop bildet.2. The method according to claim 1, »characterized in that one uses an organic solvent which forms an azeotrope with water.
3. Verfahren nach Anspruch 2, dadurch gekennzeichnet, daß man n-Butanol als organisches Lösungsmittel verwendet.3. The method according to claim 2, characterized in that n-butanol is used as the organic solvent.
4. Verfahren nach einem oder mehreren der vorangehenden Ansprüche, dadurch gekennzeichnet, daß man die Reaktion bei Temperaturen von 80-150 °C durch- führt.4. The method according to one or more of the preceding claims, characterized in that one carries out the reaction at temperatures of 80-150 ° C.
5. Verfahren nach einem oder mehreren der vorangehenden Ansprüche, dadurch gekennzeichnet, daß man die Reaktion in einem pH-Bereich von 3 bis 7 durchführt.5. The method according to one or more of the preceding claims, characterized in that one carries out the reaction in a pH range of 3 to 7.
6. Verfahren nach einem oder mehreren der vorangehenden Ansprüche, dadurch gekennzeichnet, daß man die Dipeptide der Formel (II) in Form einer wäßri- gen Lösung in die Reaktion eingesetzt werden.6. The method according to one or more of the preceding claims, characterized in that the dipeptides of the formula (II) are used in the form of an aqueous solution in the reaction.
7. 2, 5-Diketopiperazine der allgemeinen Formel III,7. 2, 5-diketopiperazines of the general formula III,
in der R5 für H oder Trifluormethyl steht. in which R 5 represents H or trifluoromethyl.
8. 2, 5-Diketopiperazin nach Anspruch 7, dadurch gekennzeichnet, daß es in der (S, S) -Konfiguration vorliegt.8. 2, 5-diketopiperazine according to claim 7, characterized in that it is in the (S, S) configuration.
9. Dipeptide der allgemeinen Formel (IV),9. dipeptides of the general formula (IV),
in der R5 für H oder Trifluormethyl steht.in which R 5 represents H or trifluoromethyl.
10. Dipeptid nach Anspruch 9, dadurch gekennzeichnet, daß es in der (S, S) -Konfiguration vorliegt10. Dipeptide according to claim 9, characterized in that it is in the (S, S) configuration
11. Verwendung der Verbindungen nach einem oder mehreren der Ansprüche 7 bis 10 zur Herstellung von cyclo [Lys- Lys] .11. Use of the compounds according to one or more of claims 7 to 10 for the preparation of cyclo [Lys-Lys].
12. Verwendung der nach Anspruch 1 hergestellten Verbindungen in der Synthese bioaktiver Verbindungen. 12. Use of the compounds prepared according to claim 1 in the synthesis of bioactive compounds.
EP01927786A 2000-04-20 2001-03-23 Method for producing 2,5-diketopiperazines, 2,5-diketopiperazines, dipeptides and the use thereof Withdrawn EP1274693A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10019879 2000-04-20
DE10019879A DE10019879A1 (en) 2000-04-20 2000-04-20 Production of known and new 2,5-diketopiperazine derivatives useful for the synthesis of bioactive compounds, e.g. cyclo(Lys-Lys)
PCT/EP2001/003322 WO2001081321A1 (en) 2000-04-20 2001-03-23 Method for producing 2,5-diketopiperazines, 2,5-diketopiperazines, dipeptides and the use thereof

Publications (1)

Publication Number Publication Date
EP1274693A1 true EP1274693A1 (en) 2003-01-15

Family

ID=7639634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01927786A Withdrawn EP1274693A1 (en) 2000-04-20 2001-03-23 Method for producing 2,5-diketopiperazines, 2,5-diketopiperazines, dipeptides and the use thereof

Country Status (6)

Country Link
US (1) US20040024180A1 (en)
EP (1) EP1274693A1 (en)
JP (1) JP2003531197A (en)
DE (1) DE10019879A1 (en)
NO (1) NO323617B1 (en)
WO (1) WO2001081321A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
BR0112969A (en) * 2000-08-04 2004-06-22 Dmi Biosciences Inc Method of using diketopiperazines and compositions containing them
SI1494732T1 (en) 2002-03-20 2008-08-31 Mannking Corp Inhalation apparatus
EP1572669A2 (en) * 2002-11-22 2005-09-14 Novo Nordisk A/S 2,5-diketopiperazines for the treatment of obesity
KR20120091266A (en) 2003-05-15 2012-08-17 디엠아이 바이오사이언시스, 인크 Treatment of t-cell mediated diseases
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
RU2403059C2 (en) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Method of improving pharmaceutical properties of particles, containing diketopiperazine and active agent
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc Therapeutic methods and compounds
KR101629154B1 (en) 2008-06-13 2016-06-21 맨카인드 코포레이션 A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2300083T3 (en) 2008-06-20 2013-07-22 Mannkind Corp INTERACTIVE DEVICE AND PROCEDURE FOR REAL-TIME PROFILING INHALATION TESTS
TWI614024B (en) 2008-08-11 2018-02-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
MX2011009512A (en) 2009-03-11 2011-11-29 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler.
SG176738A1 (en) 2009-06-12 2012-01-30 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
BR112012033060A2 (en) 2010-06-21 2018-02-27 Mannkind Corp Dry powder drug release system methods
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
RU2606624C2 (en) 2011-02-10 2017-01-10 Маннкайнд, Корп Obtaining n-protected bis-3,6-(4-aminoalkyl)-2,5-diketopiperazine
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014007657A2 (en) * 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc Implantable medical devices with improved immune tolerance and methods for production and implantation
JP6203734B2 (en) 2011-10-10 2017-09-27 アンピオ ファーマシューティカルズ，インコーポレイテッド Treatment of osteoarthritis
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
EA201490737A1 (en) 2011-10-28 2014-09-30 Ампио Фармасьютикалз, Инк. TREATMENT OF RHINITIS
CA2871126C (en) 2012-04-27 2020-07-14 Mannkind Corp. Methods for the synthesis of activated ethylfumarates and their use as intermediates
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
RU2015103314A (en) 2012-07-17 2016-09-10 Страйтмарк Холдинг Аг The method of synthesis of N-phosphonomethyliminodiacetic acid
BR112015000993B1 (en) 2012-07-17 2020-04-28 Monsanto Technology Llc method for the synthesis of an alphaaminoalkylene phosphonic acid or an ester thereof
PL2875037T3 (en) 2012-07-17 2017-06-30 Straitmark Holding Ag Method for the synthesis of n-(phosphonomethyl)glycine
EP2875036A1 (en) 2012-07-17 2015-05-27 Straitmark Holding AG Method for the synthesis of aminoalkylenephosphonic acid
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6523247B2 (en) 2013-03-15 2019-05-29 マンカインド コーポレイション Method of making microcrystalline diketopiperazine particles and method of making dry powder composition
CN114848614A (en) 2013-07-18 2022-08-05 曼金德公司 Heat stable dry powder pharmaceutical compositions and methods
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
RU2020136589A (en) 2014-08-18 2020-12-24 Ампио Фармасьютикалз, Инк. TREATMENT OF DEGENERATIVE JOINT DISEASES
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
WO2016209969A1 (en) 2015-06-22 2016-12-29 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
WO2021195265A1 (en) 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2786049A (en) * 1956-02-20 1957-03-19 Harold P Lundgren Synthesis of peptide structures
FR2629823B1 (en) * 1988-04-06 1990-11-16 Rhone Poulenc Chimie PEPTIDE PURIFICATION PROCESS
US4992552A (en) * 1988-08-31 1991-02-12 Eastman Kodak Company Process for preparation of amino acids
IL92011A0 (en) * 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
ATE141613T1 (en) * 1990-03-15 1996-09-15 Nutrasweet Co PROCESS FOR PREPARING ASPARTAME FROM A DIKETOPIPERAZINE AND NEW INTERMEDIATE PRODUCTS AND DERIVATIVES THEREFOR
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5418218A (en) * 1992-07-10 1995-05-23 The University Of Maryland At Baltimore Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5481218A (en) * 1994-09-30 1996-01-02 Telefonaktiebolaget Lm Ericsson Logarithmic converter
US5932579A (en) * 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
CA2276074A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Efficient synthesis of a chiral mediator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0181321A1 *

Also Published As

Publication number Publication date
WO2001081321A1 (en) 2001-11-01
NO20025004L (en) 2002-12-19
DE10019879A1 (en) 2001-10-25
JP2003531197A (en) 2003-10-21
NO20025004D0 (en) 2002-10-17
US20040024180A1 (en) 2004-02-05
NO323617B1 (en) 2007-06-18

Similar Documents

Publication Publication Date Title
WO2001081321A1 (en) Method for producing 2,5-diketopiperazines, 2,5-diketopiperazines, dipeptides and the use thereof
EP1876168B1 (en) Method for manufacturing beta amino alpha hydroxy carboxylic acid amides
EP0508296B1 (en) Process for the preparation of phosphorus containing L-amino acids, their derivatives and intermediates for this process
EP0617019A1 (en) Process for the preparation of 3R,5S-(+)-sodium-erythro-(E)-7-4-(4-fluorphenyl)--2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl-3,5-dihydroxy-hept-6-enoat
DE4407197A1 (en) Process for the preparation of / L / -Homoalanin-4-yl- (methyl) phosphinic acid and its salts by resolution
DE2125065A1 (en) Process for the preparation of aspartic amino acid esters
WO2018108797A1 (en) Method for producing l-glufosinate or the salts thereof using ephedrine
EP0288764A1 (en) Optically active alpha-amino aldehydes, processes for their preparation and their use in the stereoselective preparation of optically active beta-amino alcohols
EP0719279B1 (en) Process for purifying 1- n(2 -((s)-ethoxycarbonyl)-3-phenylpropyl)-n6 -trifluoroacetyl]-l-lysyl-l-prolin (lisinopril(tfa)ethylester)
DE102005012771A1 (en) Process for the preparation of 2-azabicyclo (3.3.0) octane-3-carboxylic acid derivatives
AT500490A1 (en) METHOD FOR THE PRODUCTION OF SUBSTITUTED THIAZOLINES AND THEIR INTERMEDIATE PRODUCTS
DE2946545A1 (en) METHOD FOR OBTAINING THE ENANTIOMER FORMS OF 4-CYAN-1- (N-METHYL-N- (2 &#39;- ((3&#39; &#39;, 4&#39; &#39;, - DIMETHOXYPHENYL)) - AETHYL) -AMINO) -5-METHYL-4 - (3 &#39;, 4&#39;, 5&#39;-TRIMETHOXYPHENYL) -HEXANE AND ITS SALTS
EP0496369B1 (en) Process for the preparation of racemic and optically active-1,2,3,4-tetrahydro isoquinoline 3-carboxylic acid and its precursors
DE2304054C3 (en) Process for obtaining D-penicillamine
DE2138122C3 (en) Process for obtaining D-penicillamine
EP1148042A2 (en) Method for producing optically and chemically pure (R)- and (S)-hydroxycarboxylic acids
EP0237630B1 (en) Process for the preparation of chiral glycine derivatives
DD222006A5 (en) METHOD FOR PRODUCING AN OPTICALLY ACTIVE ESTER OF AN ALPHA-CHIRAL OPTICALLY ACTIVE CARBON ACID
EP0542099A2 (en) Process for preparation of optically active 1,3-imidazolidin-4-ones and their application
EP0578163A1 (en) Process for the preparation of D,L or D,L-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid
EP0310012A2 (en) Process for the preparation of optically pure homophenyl alanine
DE602004006438T2 (en) PROCESS FOR THE PREPARATION OF ENANTIOMER ENRICHED AMINO ACIDS
EP0001821B1 (en) Resolution of d,l-alpha-amino acids and salts used therefor
WO2004092119A2 (en) Method for producing alpha-methylated cysteine and serine derivatives
Puchlopek‐Dermenci et al. Access to Chirality

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEGUSSA GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EVONIK DEGUSSA GMBH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EVONIK DEGUSSA GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100505